share_log

Johnson & Johnson | 8-K/A: Johnson & Johnson Reports Q1 2024 Results (Amendment)

Johnson & Johnson | 8-K/A: Johnson & Johnson Reports Q1 2024 Results (Amendment)

强生 | 8-K/A:强生公布2024年第一季度业绩(修正)
美股sec公告 ·  04/16 12:20
Moomoo AI 已提取核心信息
Johnson & Johnson, a leading healthcare company, filed an amended Form 8-K/A with the SEC to correct a typographical error in their initial April 16, 2024, report. The correction adjusts the full-year April 2024 guidance for operational sales from $88.0 billion to $88.9 billion. The company announced its Q1 2024 results, reporting a 2.3% increase in sales to $21.4 billion, with operational growth of 3.9% and adjusted operational growth of 4.0%. Excluding the COVID-19 vaccine, adjusted operational growth was 7.7%. First-quarter EPS rose to $2.20, with adjusted EPS increasing by 12.4% to $2.71. Johnson & Johnson also raised its full-year 2024 operational sales and adjusted operational EPS guidance. The company's performance was driven by strong sales in its Innovative Medicine and MedTech segments, with notable growth in oncology, pulmonary hypertension, immunology, and neuroscience products. Additionally, the company highlighted several regulatory approvals, product launches, and acquisitions, emphasizing its commitment to innovation and leadership in healthcare.
Johnson & Johnson, a leading healthcare company, filed an amended Form 8-K/A with the SEC to correct a typographical error in their initial April 16, 2024, report. The correction adjusts the full-year April 2024 guidance for operational sales from $88.0 billion to $88.9 billion. The company announced its Q1 2024 results, reporting a 2.3% increase in sales to $21.4 billion, with operational growth of 3.9% and adjusted operational growth of 4.0%. Excluding the COVID-19 vaccine, adjusted operational growth was 7.7%. First-quarter EPS rose to $2.20, with adjusted EPS increasing by 12.4% to $2.71. Johnson & Johnson also raised its full-year 2024 operational sales and adjusted operational EPS guidance. The company's performance was driven by strong sales in its Innovative Medicine and MedTech segments, with notable growth in oncology, pulmonary hypertension, immunology, and neuroscience products. Additionally, the company highlighted several regulatory approvals, product launches, and acquisitions, emphasizing its commitment to innovation and leadership in healthcare.
领先的医疗保健公司强生公司向美国证券交易委员会提交了经修订的8-K/A表格,以更正其2024年4月16日首次报告中的印刷错误。该修正将2024年4月全年营业销售额预期从88亿美元调整为889亿美元。该公司公布了其2024年第一季度业绩,销售额增长2.3%,达到214亿美元,运营增长3.9%,调整后的运营增长4.0%。不包括 COVID-19 疫苗,调整后的运营增长为 7.7%。第一季度每股收益升至2.20美元,调整后的每股收益增长12.4%,至2.71美元。强生公司还提高了其2024年全年营业销售额,并调整了运营每股收益预期。该公司的业绩是由其创新医学和医疗科技领域的强劲销售推动的,肿瘤学、肺动脉高压、免疫学和神经科学产品的显著增长。此外,该公司还重点介绍了几项监管批准、产品发布和收购,强调了其对医疗保健领域创新和领导地位的承诺。
领先的医疗保健公司强生公司向美国证券交易委员会提交了经修订的8-K/A表格,以更正其2024年4月16日首次报告中的印刷错误。该修正将2024年4月全年营业销售额预期从88亿美元调整为889亿美元。该公司公布了其2024年第一季度业绩,销售额增长2.3%,达到214亿美元,运营增长3.9%,调整后的运营增长4.0%。不包括 COVID-19 疫苗,调整后的运营增长为 7.7%。第一季度每股收益升至2.20美元,调整后的每股收益增长12.4%,至2.71美元。强生公司还提高了其2024年全年营业销售额,并调整了运营每股收益预期。该公司的业绩是由其创新医学和医疗科技领域的强劲销售推动的,肿瘤学、肺动脉高压、免疫学和神经科学产品的显著增长。此外,该公司还重点介绍了几项监管批准、产品发布和收购,强调了其对医疗保健领域创新和领导地位的承诺。
声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息